• Change in Albuminuria and Estimated GFR as End Points for Clinical Trials in Early Stages of CKD: A Perspective From European Regulators.

      Holtkamp, Frank; Gudmundsdottir, Hrefna; Maciulaitis, Romaldas; Benda, Norbert; Thomson, Andrew; Vetter, Thorsten; 1Dutch Medicines Evaluation Board, Utrecht, the Netherlands. 2Icelandic Medicines Agency, Reykjavík, Iceland; Landspitali - The National University Hospital of Iceland, Reykjavík, Iceland. 3Institute of Physiology and Pharmacology, Lithuanian University of Health Sciences, Kaunas, Lithuania; Lithuanian State Medicines Control Agency, Kaunas, Lithuana. 4German Federal Institute for Drugs and Medical Devices, Bonn, Germany. 5European Medicines Agency, Amsterdam, the Netherlands. 6European Medicines Agency, Amsterdam, the Netherlands. Electronic address: thorsten.vetter@ema.europa.eu. (W.B. Saunders, 2019-10-28)